The evaluation of the influence of growth hormone therapy on growing process and metabolic functions in patients after treatment of craniopharyngioma;Ocena wpływu terapii hormonem wzrostu na przebieg wzrastania i funkcje metaboliczne u pacjentów po leczeniu craniopharyngioma

Pediatric Endocrinology, Diabetes and Metabolism

Volumn 16, Issue 1, 2010, Pages 19-24

  Okońska, Maja ^a   Birkholz, Dorota ^a   Korpal Szczyrska, Maria ^a   Adamkiewicz Drozyńska, Elzbieta ^a   Alska, Anna ^a   Magnuszewska, Hanna ^a  

^a Uniwersyteckiego Centrum Klinicznego   (Poland)

Author keywords

BMI; Cholesterol; Craniopharyngioma; Growth hormone therapy; Growth velocity

Indexed keywords

CHOLESTEROL; CORTICOTROPIN; FOLLITROPIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; RECOMBINANT GROWTH HORMONE; THYROTROPIN; TRIACYLGLYCEROL;

AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CRANIOPHARYNGIOMA; DRUG EFFECT; FEMALE; HUMAN; HYPOPITUITARISM; MALE; POSTOPERATIVE PERIOD; REMISSION;

EID: 84904847377     PISSN: 1234625X     EISSN: 20838441     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cannavo S., Marini F., Trimarchi F. : Patients with craniopharyngiomas: Therapeutical difficulties with growth hormone. J. Endocrinol. Invest., 2008, 31, supl. do nr 9, 56-60.
2. Müller H.L.: Childhood craniopharyngioma. Horm. Res., 2008, 69, 193-202.
3. Roszkowski M.: Przewodnik czaszkowo gardłowy (czaszkogardlak) - craniopharyngioma. [w:] Nowotwory ośrodkowego układu nerwowego u dzieci diagnostyka i leczenie. D. Perek, M. Roszkowski, Warszawa 2006, 299-311.
4. Karavitaki N., Brufani C., Warner J.T. i wsp.: Craniopharyngiomas in children and adults: systemic analysis of 121 cases with long-term follow-up. Clin. Endocrinol., 2005, 62, 397-409.
5. Chakrabarti I., Amar A.P., Couldwell W. i wsp.: Long-term neurological, visual, and endocrine outcomes following transnasal resection of craniopharyngioma. J. Neurosurg., 2005, 102, 650-657.
6. Srinivasan S., Ogle G.D., Garnett S.P. i wsp.: Features of the metabolic syndrome after childhood craniopharyngioma. J. Clin. Endocrinol. Metab., 2004, 89, 81-86.
7. Pinkney J., Wilding J., Wiliams G. i wsp.: Hypothalamic obesity in humans: what do we know and what can be done? Obes. Rev., 2002, 3, 27-34.
8. DeVile C.J, Grant D.B, Hayward R.D. i wsp.: Growth and endocrine sequelae of cranipharyngioma. Arch. Dis. Child., 1996, 75, 108-114.
9. Pinto G., Bussieres L., Recasens C., i wsp.: Hormonal factors influencing weight and growth pattern in craniopharyngioma. Horm. Res., 2000, 53, 163-169.
10. Tiulpakov A.N, Mazerkina N.A, Brook C.G.D. i wsp.: Growth in children with craniopharyngioma following surgery. Clin. Endocrinol., 1998, 49, 733-738.
11. Monson J.P.: Long-term experience with GH replacement therapy: efficacy and safety. Eur. J. Endocrinol., 2003, 148, S9-S14.
12. Karavitaki N., Warner J.T., Marland A. i wsp.: GH replacement does not increase the risk of recurrence in patients with craniopharyngioma. Clin. Endocrinol., 2006, 64, 556-560.
13. Trivin C., Busiah K., Mahlaoui N. i wsp.: Childhood craniopharyngioma: greater hypothalamic involvement before surgery is assiociated with higher homeostasis model insulin resistance index. BMC Pediatrics, 2009, 9, 24.
14. Bercu B.B., Murray F.T., Frasier S.D. i wsp.: Long-term therapy with recombinant human growth hormone (Saizen®) in children with idiopathic and organic growth hormone deficiency. Endocrine, 2001, 15, 43-49.
15. Plotnik L., Rapaport R., Desrosiers P. i wsp.: Update from the GHMonitor Observational Registry in Children Treated with Recombinant Human Growth Hormone (Saizen®). Pediatr. Endocrinol. Rev., 2009, 6, supl. 2, 278-282.
16. Rosenfalck A.M., Mahgsoudi S., Fisker S. i wsp.: The effect of 30 months of low dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptidekinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J. Clin. Endocrinol. Metab., 2000, 85, 4173-4181.
17. Fernholm R., Bramnerr M., Hagg E. i wsp.: Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J. Clin. Endocrinol. Metab., 2000, 85, 4104-4112.
18. Chrisoulidou A., Beshyah S.A., Rutherford O. i wsp.: Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J. Clin. Endocrinol. Metab., 2000, 85, 3762-3769.
19. Birkholz D., Korpal-Szczyrska M., Kamińska H. i wsp.: Wpływ zabiegu operacyjnego i radioterapii na tempo wzrastania i rozwoju dzieci z guzami ośrodkowego układu nerwowego. Medycyna Wieku Rozwojowego, 2005, IX, 3, cz. II, 463-469.
20. Riedl M., Ludvik B., Pacini G i wsp.: The increased insulin sensitivity in growth hormone replacement therapy. Eur. J. Clin. Invest., 2000, 30, 771-778.
21. Florakis D., Hung V., Kaltsas G. i wsp.: Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin. Endocrinol., 2000, 53, 453-459.
22. Darendeliler F., Karagiannis G., Wilton P.: Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: safety update from the KIGS database. Horm. Res., 2007, 68, supl. 5, 41-47.